As one of the innovative antibody drug R&D enterprises with the richest and most diversified pipelines in China, we have developed over 30 innovative drug candidates with complete proprietary intellectual property rights, including 6 bispecific antibodies. More than 80 clinical trials of 17 drug candidates have been launched in China, the US, Australia, New Zealand, etc. with 14 clinical trials under pivotal/phase III trial.